A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs ALT 803 (Primary) ; ALT 803 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 19 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 13 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top